HLOSF (Healios KK) E10: $-0.48 (As of Mar. 2026)


HLOSF Healios KK HLOSF
57 GF Score
Price $1.80
GF Value $0.42
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Healios KK E10?

Healios KK HLOSF 57 E10 is $-0.48 as of Mar. 2026. GuruFocus rates HLOSF with a GF Score™ of 57/100 and a GF Value™ of $0.42 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Healios KK's adjusted earnings per share data for the three months ended in Mar. 2026 was $-0.174. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.48 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-29), Healios KK's current stock price is $1.80. Healios KK's E10 for the quarter that ended in Mar. 2026 was $-0.48. Healios KK's Shiller PE Ratio of today is .


Healios KK  (OTCPK:HLOSF) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Healios KK E10 Related Terms


Healios KK E10 Historical Data

* Premium members only.

The historical data trend for Healios KK's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Healios KK E10 Chart

Healios KK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.64 -0.60

Healios KK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.61 -0.62 -0.69 -0.60 -0.48

HLOSF vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, Healios KK's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Healios KK Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Healios KK's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Healios KK's Shiller PE Ratio falls into.


HLOSF
57GF Score
Healios KK HLOSF
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Healios KK E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Healios KK's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.174/112.7000*112.7000
=-0.174

Current CPI (Mar. 2026) = 112.7000.

Healios KK Quarterly Data

per share eps CPI Adj_EPS
201606 -0.121 98.100 -0.139
201609 -0.109 98.000 -0.125
201612 -0.070 98.400 -0.080
201703 -0.113 98.100 -0.130
201706 0.036 98.500 0.041
201709 -0.177 98.800 -0.202
201712 -0.106 99.400 -0.120
201803 -0.106 99.200 -0.120
201806 -0.511 99.200 -0.581
201809 -0.133 99.900 -0.150
201812 -0.188 99.700 -0.213
201903 -0.171 99.700 -0.193
201906 -0.194 99.800 -0.219
201909 -0.186 100.100 -0.209
201912 -0.329 100.500 -0.369
202003 -0.229 100.300 -0.257
202006 -0.243 99.900 -0.274
202009 -0.259 99.900 -0.292
202012 -0.280 99.300 -0.318
202103 -0.231 99.900 -0.261
202106 -0.151 99.500 -0.171
202109 -0.316 100.100 -0.356
202112 -0.247 100.100 -0.278
202203 -0.223 101.100 -0.249
202206 -0.244 101.800 -0.270
202209 -0.086 103.100 -0.094
202212 -0.145 104.100 -0.157
202303 -0.086 104.400 -0.093
202306 -0.073 105.200 -0.078
202309 -0.068 106.200 -0.072
202312 -0.170 106.800 -0.179
202403 -0.194 107.200 -0.204
202406 -0.038 108.200 -0.040
202409 -0.119 108.900 -0.123
202412 0.021 110.700 0.021
202503 -0.179 111.100 -0.182
202506 -0.141 111.700 -0.142
202509 0.051 112.000 0.051
202512 0.083 113.000 0.083
202603 -0.174 112.700 -0.174

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-0.48 mean?
Healios KK (HLOSF) has a E10 of $-0.48 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Healios KK and its competitors.
Is Healios KK's E10 too high?
Healios KK's current E10 is $-0.48. Overall, Healios KK has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Healios KK's E10 compare to VRTX and REGN?
Healios KK's E10 of $-0.48 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Healios KK and its competitors. Healios KK's current E10 is $-0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healios KK stock overvalued right now?
Based on GuruFocus' analysis, Healios KK (HLOSF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.42, compared to a current price of $1.80 — trading 328.6% above its estimated fair value. The current E10 is $-0.48. Healios KK's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Healios KK (HLOSF), the current E10 is $-0.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Healios KK (HLOSF) Overvalued in 2026?

Based on GuruFocus' analysis, Healios KK stock appears to be overvalued. The current stock price of $1.80 is trading 328.6% above its estimated GF Value™ of $0.42. GuruFocus considers Healios KK to be Significantly Overvalued.

Key valuation signals for HLOSF:

  • E10: $-0.48
  • GF Value™: $0.42 vs. price of $1.80 (328.6% above fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the HLOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Healios KK Business Description

Other Exchanges 4593:Japan6VX:Germany
Address 1-1-2 Yurakucho, Hibiya Mitsui Tower 12Floor, Work Styling, Chiyoda-ku, Tokyo, JPN, 100-0006
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
57GF Score

Get the complete analysis for HLOSF

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.80
Price
$0.42
GF Value